NASH

[Acta Pharmacologica Sinica] The authors review the current knowledge on miR-27, miR-24, and miR-23 in non-alcoholic fatty liver disease (NAFLD) pathogenesis and discuss their potential significance in NAFLD diagnosis and therapy.

[Aligos Therapeutics, Inc. (Globe Newswire, Inc.)] Aligos Therapeutics, Inc. announced that the company has started dosing in the first cohort of healthy volunteers in Study ALG-055009-301 evaluating ALG-055009 for the treatment of nonalcoholic steatohepatitis (NASH).

[Nature Communications] Hepatocyte-specific deletion of Mettl3 drove nonalcoholic fatty liver-to-NASH progression by increasing CD36-mediated hepatic free fatty acid uptake and CCL2-induced inflammation, which is due to increased chromatin accessibility in the promoter region of Cd36 and Ccl2.

[PLoS One] Scientists characterized hepatic stellate cells obtained from patients carrying the wild type and the heterozygous or homozygous PNPLA3 I148M and investigated the effect of genotype and PNPLA3 downregulation on baseline and TGF-β-stimulated fibrotic gene expression.

[Aligos Therapeutics, Inc. (Globe Newswire, Inc.)] Aligos Therapeutics, Inc. announced that the company has started dosing in the first cohort of healthy volunteers in Study ALG-055009-301 evaluating ALG-055009 for the treatment of nonalcoholic steatohepatitis (NASH).

[iScience] The authors describe advances in preclinical models for non-alcoholic fatty liver disease-non-alcoholic steatohepatitis, the recent introduction of novel technologies in this space, and their importance for drug discovery endeavours in the future.